Our Story

MiraKind was founded as a nonprofit research organization in 2013 by Joanne Weidhaas, MD, PhD., following her co-discovery of the KRAS-variant, an inherited genetic mutation associated with an increased risk of cancer. Every year scientists like Dr. Weidhaas discover hundreds of potentially important genetic markers that could benefit millions of patients. Unfortunately, very few of these discoveries make it beyond the research lab for validation.  MiraKind is working to change this by breaking down barriers between doctors, scientists, and patients to ask the questions that will lead to actionable strategies to reduce cancer risk. Our research is patient-centered from start to finish, with the ultimate goal of empowering patients so that, together with their doctors, they can make the best decisions for their health and lifestyle. Our research is guided by one question: How can we enhance health and longevity by preventing cancer for all individuals?

Key to helping us achieve our goals is YOU:

  • Ask questions to help shape our future research.
  • Participate in a study to advance our understanding of the KRAS-variant.
  • Tell your story so that others may benefit from your experience.
  • Make a donation, spread the word and be part of a movement that believes knowledge is power.
  • Join the MiraKind community today.

Our work can save thousands of lives.
Join us and help humankind!

Joanne Weidhaas, M.D., Ph.D.


In 2006, Joanne Weidhaas, MD, PhD, physician-scientist and former Head of Breast Radiation Oncology Service at Yale University, co-discovered the KRAS-variant, a genetic marker that has significant implications for women’s health. It predicts endometriosis and associated infertility, breast, ovarian and lung cancer, and unique response to treatments for these conditions.

Despite her discovery’s significance, Joanne foresaw the difficulty in translating its benefits from the lab bench to her and other doctors’ patients. Still, she committed to the arduous process of development and validation to ensure her research became commercially viable.  Joanne found little support, resources or guidance available for navigating this complex process and no room in the financially motivated commercial lab business to develop tests that could advance patient-centered outcomes like disease prevention.

Now, after more than 10 years as a research scientist and radiation oncologist at Yale University, Joanne is passionate about ensuring genetic discoveries reach the doctors and patients they can help.  That’s why she founded MiraKind, a research institute that allows individuals to directly participate in studies to validate important genetic markers and discover patient-centered applications of them.


Sara Rosenthal

Director, women's health

Sara is a strategic advisor for MiraKind, assisting with strategic planning, finance and fundraising.


Hans Galland


Hans is an investment professional with ten years experience in transaction, asset management and corporate finance advice. Hans serves as treasurer of the board for MiraKind.


Tina Kelly

Patient Advisor

Tina is a patient advisor to MiraKind and an advocate for women with the KRAS-variant. As a breast cancer survivor, she is passionate about empowering women to protect their health.